Gene therapy can effectively treat various diseases, but for some debilitating conditions like muscular dystrophies there is ...

MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the third quarter ended September 30, ...

Analysts did not seem very concerned by the treatment-related serious adverse event, noting that NGN-401 was well-tolerated ...

Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm’s clinical program is a LVV-based gene therapy for ...

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

Matica Biotechnology (Matica Bio), a leading contract development and manufacturing organization (CDMO) for viral vectors, ...

Dyno Therapeutics has recently announced the formation of a new strategic partnership with Swiss pharma giant Roche to ...

Australian scientists have successfully used an innovative gene therapy technique in the lab to combat a key cause of vision ...

With the formation of a new strategic partnership, Dyno Therapeutics is responsible for the development of novel AAV capsids.

An epigenetic editing therapy, MDL-101 includes a guide nucleotide targeting the LAMA1 gene — a close homolog of the ...